Modulating Nervous System Plasticity via Molecular Pathway Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nervous system damage and disorders, such as stroke and neuropsychiatric conditions, lack effective pharmacological agents to enhance recovery and improve cognitive function, particularly in modulating synaptic plasticity and related biological pathways.
Innovation Solution
A method involving the identification of differentially regulated genes and pathways in the nervous system under conditions that modify plasticity, followed by the administration of plasticity-modifying agents, such as IGF1 pathway activators or JAK/STAT pathway modulators, to promote recovery and reorganization, combined with proteolysis-enhancing agents like tPA for focal delivery via drug delivery devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current supportive care and rehabilitation therapy are used for stroke survivors, then functional limitations can be managed, but there are no pharmacological agents that have demonstrated efficacy in improving long-term outcome
Solution Approach 1:
The patent identifies and targets molecular pathways and genes that are differentially regulated during critical periods of nervous system plasticity, performing preliminary molecular characterization before therapeutic intervention. This allows for the development of pharmacological agents that can be administered at optimal times to enhance recovery, rather than relying solely on post-injury supportive care.
Solution Approach 2:
The patent modulates specific molecular parameters (gene expression, protein activity, pathway regulation) that control nervous system plasticity. By changing these molecular parameters through pharmacological intervention, the patent aims to enhance recovery outcomes that cannot be achieved through conventional supportive care alone.
2Speed
If thrombolytic therapy (tPA) is administered within 3 hours of stroke onset, then blood flow disruption can be addressed, but the treatment window is limited and functional recovery is not guaranteed
Solution Approach 1:
The patent performs preliminary identification and characterization of plasticity-related genes and pathways before the stroke event, enabling the development of therapies that can be activated at the optimal time to enhance recovery, rather than relying solely on immediate thrombolytic intervention.
Solution Approach 2:
The patent extends the therapeutic window by targeting molecular pathways that remain active during critical periods of plasticity. This allows for continuous or prolonged pharmacological intervention beyond the immediate 3-hour window, maintaining useful action on nervous system recovery processes.
3Reliability
If spinal cord injury patients receive improved supportive care, then survival rate increases, but therapeutic options remain limited and focus remains on rehabilitation
Solution Approach 1:
The patent conducts preliminary molecular analysis of spinal cord injury models to identify differentially regulated genes and pathways, enabling the development of targeted pharmacological therapies that complement supportive care and expand therapeutic options beyond conventional rehabilitation.
4Ease of operation
If neurodevelopmental disorders are treated with behavioral therapies alone, then treatment approach is simple, but success is limited
Solution Approach 1:
The patent identifies and modulates molecular parameters (gene expression, signaling pathways) that underlie neurodevelopmental disorders. This provides a biological basis for enhanced treatment efficacy beyond behavioral therapies alone, while maintaining operational simplicity through targeted pharmacological intervention.
Data Source
AI summary
The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacological agents that modify plasticity. The invention also identifies biological pathways that are enriched in genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The present invention further provides methods and compositions for modifying plasticity in the nervous system of a subject. The invention includes a method for modifying plasticity in the nervous system of a subject comprising administering a plasticity-modifying agent to the subject, wherein the plasticity-enhancing agent modulates a gene or pathway that is differentially regulated in developmental conditions that alter nervous system plasticity (e.g., DR or MD). The methods and compositions may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.